UNIVERSITY OF ALABAMA AT BIRMINGHAM

Heersink School of Medicine awarded nine staff members the 2024 Dean’s Excellence Awards for Staff, recognizing their exceptional contributions to education, clinical care, and research.

Daily cigarette smokers may qualify for a UAB research study involving online screening, 8 contacts over 6 months, and trying varenicline or nicotine patches/lozenges. Compensation available. More info at https://redcap.musc.edu/surveys/?s=8JWFT9XFY3FYR7Y3.

Dupixent reduced COPD exacerbations and improved lung function in adults with type 2 inflammation, according to BOREAS and NOTUS phase 3 studies. Dupixent was approved by the European Medicines Agency as an add-on treatment for uncontrolled COPD patients on maximal inhaled therapy. The pooled analysis showed a 31% reduction in exacerbations and a 147 mL improvement in lung function compared to placebo, with safety consistent with known profiles.

Dupixent showed a 31% reduction in COPD exacerbations and improved lung function in a pooled analysis of BOREAS and NOTUS phase 3 studies, reinforcing its clinical benefit for uncontrolled COPD patients with type 2 inflammation.

UAB startup TIXiMED Inc. gains FDA clearance for TIX100, an oral Type 1 diabetes drug, to proceed to clinical trials, potentially easing the burden of daily insulin injections.

A cluster analysis in the Deep South revealed that Black/African American individuals have an increased risk for severe insulin-deficient diabetes, a subtype of Type 2 diabetes, which can lead to more appropriate treatments and improved outcomes.